The short answer is yes, but it's essential to approach this combination with careful guidance from a healthcare provider
By inhibiting glucagon release from pancreatic alpha cells, Semaglutide helps prevent excessive production of glucose in the liver
The mechanism likely involves improved insulin sensitivity directing fuel utilization toward fat oxidation, combined with reduced caloric intake that still provides adequate protein for muscle maintenance in most cases
They can help with eating disorders and weight-related mental health issues
The FDA has documented several concerns specifically involving compounded GLP-1 products: dosing errors (including doses far exceeding the FDA-approved label), improper storage during shipping affecting medication integrity, reports of fraudulent or counterfeit compounded products, adverse event reports associated with compounded GLP-1 use, and the use of semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) that should not be used for compounding
This fundamental difference in mechanism leads to substantially different outcomes
